Clinical Trial: Mixed Chimeric Transplantation for Primary Amyloidosis

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Mixed Chimeric Transplantation for Primary Amyloidosis

Brief Summary: To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Detailed Summary:
Sponsor: Stanford University

Current Primary Outcome: Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Toxicity of therapy
  • Changes in marrow and serum abnormalities
  • Improvement in end-organ function.


Original Secondary Outcome:

  • - Toxicity of therapy
  • - Changes in marrow and serum abnormalities
  • - Improvement in end-organ function.


Information By: Stanford University

Dates:
Date Received: September 13, 2005
Date Started: December 2000
Date Completion: September 2006
Last Updated: October 5, 2007
Last Verified: October 2007